Humulin I Kwikpen (Isophane) (Insulin Human (Rdna))

Humulin I Kwikpen is indicated for the management of hyperglycemia in adults and children with diabetes.

• Type 1 diabetes mellitus as part of a basal‑bolus regimen.
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct therapy with rapid‑acting insulin analogues to achieve target glucose levels.
• Use during periods of increased insulin resistance such as illness or steroid therapy.
• Replacement therapy in patients transitioning from other intermediate‑acting insulins.

• Humulin I Kwikpen contains insulin human (isophane), a recombinant form of endogenous insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and enhancing glucose uptake. It also suppresses hepatic gluconeogenesis, thereby lowering circulating glucose concentrations throughout the body.

Adverse reactions to Humulin I Kwikpen may vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, presenting as shakiness, sweating, or dizziness.
• Local injection‑site reactions such as erythema, swelling, itching or bruising.
• Small, reversible changes in subcutaneous fat (lipodystrophy) at the site of administration.
• Gradual weight gain that may accompany improved blood‑glucose control.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms, possible loss of consciousness or seizures.
• Immediate hypersensitivity reactions, including urticaria, angio‑edema or anaphylactic shock.
• Generalized edema or fluid retention leading to peripheral swelling.
• Development of painful lipohypertrophy or large indurated nodules at injection sites.

Before using Humulin I Kwikpen, patients and clinicians should consider several precautionary measures to ensure safe and effective therapy.

• Verify blood glucose levels before each injection to avoid hypoglycemia.
• Rotate injection sites within the abdomen, thigh or upper arm to reduce lipodystrophy.
• Do not use the pen if the solution is cloudy, discolored, or contains particles.
• Adjust dose during periods of illness, increased physical activity, or when taking corticosteroids.
• Monitor for signs of allergic reaction, especially after the first few administrations.
• Use with caution in patients with renal or hepatic impairment, as insulin clearance may be altered.
• Pregnant or breastfeeding women should discuss risks and benefits with their healthcare provider.

Humulin I Kwikpen can interact with other medications, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concomitant use of other insulin products or insulin secretagogues without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, making detection difficult.

Use with caution

• Oral antidiabetic agents (e.g., metformin, sulfonylureas) that may potentiate insulin’s glucose‑lowering effect.
• Corticosteroids, which can increase insulin resistance and require dose escalation.
• Diuretics, especially thiazides, that may raise blood glucose levels.
• Alcohol consumption, which can cause unpredictable glucose fluctuations.